In this issue:
Association of pituitary dysfunction induced by immune checkpoint inhibitors and OS in NSCLC
Hyper progressive disease during immunotherapy treatment of NSCLC
NOTCH mutation as a predictor of immunotherapy outcomes in NSCLC
Lutathera plus nivolumab for neuroendocrine tumours of the lung
Cryoablation for treatment of metastatic lung tumours
Prognostic risk score for pStage I lung adenocarcinoma
Osimertinib plus bevacizumab for metastatic EGFR+ lung cancers
Low dose erlotinib for elderly or frail patients with EGFR+ NSCLC
Outcomes in patients with thoracic malignancies infected with COVID-19
Lung cancer screening using circulating tumour cells
Impact of neurological symptoms survival in NSCLC patients with brain metastases
Please login below to download this issue (PDF)